Previous 10 | Next 10 |
home / stock / mycof / mycof news
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) is basically shutting down as the company has burned through its cash and is closing its research operations in Denver Colorado. The psilocybin company reported financial results for the six months ending June 30, 2022, with ...
Mydecine Innovations Group press release ( OTCPK:MYCOF ): Q2 GAAP EPS of -C$0.35. The Company had C$324,146 in cash and cash equivalents as of June 30, 2022. For further details see: Mydecine Innovations Group GAAP EPS of -C$0.35
DENVER, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported financial results for the six months en...
MYDECINE INNOVATIONS GROUP ANNOUNCES RESIGNATION OF DIRECTORS Canada NewsWire DENVER , Aug. 12, 2022 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the ne...
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology company aiming to transform the treatment of mental health and addiction disorders, has successfully synthesized multiple short-acting MDMA analogs and has filed a patent covering these novel molecules. Experts...
DENVER, July 19, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, announced it has succ...
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared MYCO-001 in a recent Investigatio...
DENVER, June 17, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology aiming to transform the treatment of mental health and addiction disorders, today announced that the U.S. Food...
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology company aiming to transform the treatment of mental health and addiction disorders, is sharing key clinical-trial and drug-development updates as well as financial status; the company also appointed a new membe...
DENVER, June 09, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today provided an upd...
News, Short Squeeze, Breakout and More Instantly...
(TheNewswire) Vancouver, British Columbia, July 5, 2024— TheNewswire – Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) is pleased to confirm that further to its news release dated June 13, 2024, ...
(TheNewswire) Vancouver, British Columbia, May 31, 2024 - TheNewswire - Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) provides this update on the status of a management cease trade order granted on May 2...
(TheNewswire) Vancouver, British Columbia – TheNewswire - May 16, 2024— Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) provides this update on the status of a management cease trade order gr...